Clinical trials - Press Releases

Date	Title	Company
20-Jul-2023	RenovoRx and Imugene Announce Collaboration to Deliver Oncolytic Virus Therapy Using Proprietary Trans-Arterial Micro-Perfusion (TAMP) Platform	RenovoRx/Imugene
19-Jul-2023	Destiny Pharma plc ("Destiny Pharma" or "the Company") Board changes including appointment of new CEO	Destiny Pharma
18-Jul-2023	AARDEX Group Announced as Founder Member of CancerX Initiative to Drive Innovation in the Fight Against Cancer	AARDEX Group
18-Jul-2023	Trial launched to combat progressive shortsightedness in children using virtual reality delivered app	Lindus Health / Dopavision
17-Jul-2023	EnteroBiotix appoints Elmar Schnee as Executive Chairman	EnteroBiotix
17-Jul-2023	Santen launches Roclanda®, with the ROCK inhibitor netarsudil, in the UK – representing the first new class of medication for the medical management of glaucoma in Europe in 25 years	Santen
14-Jul-2023	Depression now one of the top five most studied disease areas in clinical development, finds new Phesi global analysis	Phesi
12-Jul-2023	New Greenphire Study Finds Unified Technology Essential for Enhancing Patient Experience and Engagement in Clinical Trials	Greenphire
11-Jul-2023	Skyelarke furthers its mission to break down barriers to clinical trial participation, with new SkyePay enhancements	Skyelarke
11-Jul-2023	Phastar's B Corp™ certification affirms its status as a 'force for good' organization	Phastar
07-Jul-2023	Numaferm and Zoetis Sign License Agreement to Collaborate on Developing and Producing Proteins and Peptides	Numaferm
07-Jul-2023	AiCuris Announces Strategic Shift to Focus Development and Commercialization of Anti-infectives for Immunocompromised Patients	AiCuris
07-Jul-2023	PSYCH Symposium 2023	PSYCH CAPITAL PLC
06-Jul-2023	ACTIPHAGE TB ENTERS THIRD CLINICAL TRIAL AIMED AT VALIDATING ITS UTILITY AS A TUBERCULOSIS DIAGNOSTIC	PBD Biotech
06-Jul-2023	TolerogenixX expands Phase II immune-tolerance trial and closes EUR 12 million Series A financing	TolerogenixX
04-Jul-2023	Psychedelics clinical trial start-up Clerkenwell Health to sponsor PSYCH Symposium London 2023	Clerkenwell Health
04-Jul-2023	Sosei Heptares Doses First Subject in Phase I Trial with HTL0048149, a First-in-Class GPR52 Agonist for Schizophrenia	Sosei Heptares
04-Jul-2023	Creative Diagnostics Introduces qPCR Assay for Rapid Virus Detection and Quantification	Creative Diagnostics
30-Jun-2023	Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer	Enterome
30-Jun-2023	DelSiTech announces positive topline clinical data from phase 1 trial with its sustained release eye drop platform	DelSiTech